Polish biopharmaceutical company JJP Biologics receives EMA approval for first-in-human clinical trial of anti-inflammatory monoclonal antibody JJP-1212.
JJP Biologics, a private Polish biopharmaceutical company, has received a positive decision from the European Medicines Agency to execute a first-in-human clinical trial of its anti-inflammatory monoclonal antibody JJP-1212 (anti-CD89). The Phase I study aims to evaluate the treatment for various IgA-mediated autoimmune and fibrotic diseases, making JJP Biologics the first Polish company to receive approval for a novel therapeutic monoclonal antibody clinical trial.
May 29, 2024
6 Articles